Guido Ferrari

List of Publications by Year
in descending order

234 papers	15,758 citations	19608 61 h-index	21474 114 g-index
248 all docs	248 docs citations	248 times ranked	11670 citing authors

#	Article	IF	Citations
1	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. Journal of Infectious Diseases, 2022, 225, 856-861.	1.9	22
2	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. Journal of Clinical Investigation, 2022, 132, .	3.9	9
3	Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. Npj Vaccines, 2022, 7, 18.	2.9	2
4	Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. MSphere, 2022, 7, e0083921.	1.3	2
5	Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges. Frontiers in Immunology, 2022, 13, 788619.	2.2	4
6	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	2.0	14
7	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
8	Development of flow cytometryâ€based assays to assess the ability of antibodies to bind to <scp>SARSâ€CoV</scp> â€2â€infected and spikeâ€transfected cells and mediate <scp>NK</scp> cell degranulation. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, , .	1.1	4
9	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. Science Advances, 2022, 8, eabm3948.	4.7	1
10	A Cytometrist's Guide to Coordinating and Performing Effective COVID â€19 Research. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 11-18.	1.1	2
11	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	1.9	16
12	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathogens, 2021, 17, e1009363.	2.1	19
13	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	2.9	46
14	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. Frontiers in Immunology, 2021, 12, 678511.	2.2	11
15	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine, 2021, 39, 3879-3891.	1.7	3
16	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Science Immunology, 2021, 6, .	5.6	53
17	Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions. Vaccines, 2021, 9, 975.	2.1	5
18	Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DARTÂ® Molecules. Frontiers in Immunology, 2021, 12, 710273.	2.2	4

#	Article	IF	Citations
19	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. Retrovirology, 2021, 18, 35.	0.9	7
20	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. Journal of Virology, 2021, , JVI0164321.	1.5	7
21	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathogens, 2021, 17, e1010046.	2.1	6
22	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. Frontiers in Immunology, 2021, 12, 787603.	2.2	1
23	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV,the, 2020, 7, e688-e698.	2.1	58
24	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. Journal of Virology, 2020, 95, .	1.5	5
25	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. Aids, 2020, 34, 1923-1931.	1.0	4
26	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. MBio, 2020, 11, .	1.8	6
27	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathogens, 2020, 16, e1008764.	2.1	37
28	Engineering antibody-based molecules for HIV treatment and cure. Current Opinion in HIV and AIDS, 2020, 15, 290-299.	1.5	6
29	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	30
30	Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers. Microorganisms, 2020, 8, 1722.	1.6	7
31	HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. MSphere, 2020, 5, .	1.3	6
32	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. Cell Reports, 2020, 31, 107624.	2.9	43
33	CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses. Vaccines, 2020, 8, 284.	2.1	7
34	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelopeâ€“specific plasma cells and humoral immunity in nonhuman primates. Science Immunology, 2020, 5, .	5.6	90
35	Curing HIV: Seeking to Target and Clear Persistent Infection. Cell, 2020, 181, 189-206.	13.5	126
36	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. PLoS Pathogens, 2020, 16, e1008083.	2.1	50

#	Article	IF	Citations
37	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Cell Reports, 2020, 30, 1553-1569.e6.	2.9	21
38	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	1.5	19
39	Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DARTÂ® Molecules. Frontiers in Immunology, 2020, 11, 713.	2.2	10
40	HIV vaccine delayed boosting increases Env variable region 2â€“specific antibody effector functions. JCI Insight, 2020, 5, .	2.3	18
41	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. JCI Insight, 2020, 5, .	2.3	25
42	In vivo delivery of synthetic DNAâ€“encoded antibodies induces broad HIV-1â€“neutralizing activity. Journal of Clinical Investigation, 2020, 130, 827-837.	3.9	30
43	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. Journal of Clinical Investigation, 2020, 130, 5157-5170.	3.9	22
44	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. Scientific Reports, 2019, 9, 10165.	1.6	7
45	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. Journal of Infectious Diseases, 2019, 219, 1755-1765.	1.9	7
46	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. Journal of Virology, 2019, 93, .	1.5	26
47	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Science Translational Medicine, 2019, 11, .	5.8	46
48	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e737-e749.	2.1	43
49	Antibody Fabâ€Fc properties outperform titer in predictive models of <scp>SIV</scp> vaccineâ€induced protection. Molecular Systems Biology, 2019, 15, e8747.	3.2	17
50	Monkeying Around: Using Non-human Primate Models to Study NK Cell Biology in HIV Infections. Frontiers in Immunology, 2019, 10, 1124.	2.2	21
51	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. Frontiers in Immunology, 2019, 10, 1025.	2.2	37
52	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. Journal of Virology, 2019, 93, .	1.5	37
53	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. Molecular Therapy - Nucleic Acids, 2019, 15, 36-47.	2.3	79
54	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Frontiers in Immunology, 2019, 10, 2875.	2.2	20

#	Article	IF	Citations
55	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. Frontiers in Immunology, 2019, 10, 2741.	2.2	25
56	Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2019, 93, .	1.5	18
57	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. Journal of Virology, 2019, 93, .	1.5	25
58	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. Journal of Virology, 2019, 93, .	1.5	13
59	Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. AIDS Research and Human Retroviruses, 2019, 35, 310-325.	0.5	12
60	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. Journal of Clinical Investigation, 2019, 129, 4838-4849.	3.9	95
61	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. Journal of Clinical Investigation, 2019, 129, 4769-4785.	3.9	27
62	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cellâ€mediated cytotoxicity assay. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 436-447.	1.1	18
63	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	1.5	10
64	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. Journal of Infectious Diseases, 2018, 217, 1280-1288.	1.9	32
65	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. Journal of Virology, 2018, 92, .	1.5	30
66	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	1.5	45
67	Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. Journal of Virology, 2018, 92, .	1.5	96
68	Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. AIDS Research and Human Retroviruses, 2018, 34, 193-205.	0.5	17
69	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	2.0	26
70	A-102 Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 33-33.	0.9	1
71	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Reports, 2018, 25, 3123-3135.e6.	2.9	23
72	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. Cell, 2018, 175, 387-399.e17.	13.5	78

#	Article	IF	Citations
73	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Reports, 2018, 25, 107-117.e3.	2.9	79
74	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	1.5	39
75	Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. Open Forum Infectious Diseases, 2018, 5, ofy138.	0.4	2
76	Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques. MSphere, 2018, 3, .	1.3	17
77	Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. Mucosal Immunology, 2018, 11, 1716-1726.	2.7	15
78	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Journal of Virology, 2018, 92, .	1.5	39
79	Tandem bispecific broadly neutralizing antibody â€" a novel approach to HIV-1 treatment. Journal of Clinical Investigation, 2018, 128, 2189-2191.	3.9	3
80	DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. Vaccine, 2017, 35, 929-937.	1.7	7
81	<scp>HIV</scp> antibodies for treatment of <scp>HIV</scp> infection. Immunological Reviews, 2017, 275, 313-323.	2.8	59
82	Beyond Viral Neutralization. AIDS Research and Human Retroviruses, 2017, 33, 760-764.	0.5	36
83	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Journal of Virology, 2017, 91, .	1.5	29
84	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology, 2017, 91, .	1.5	26
85	An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. Vaccine Journal, 2017, 24, .	3.2	8
86	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. Journal of Virology, 2017, 91, .	1.5	5
87	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	5.8	137
88	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	0.5	18
89	Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. AIDS Research and Human Retroviruses, 2017, 33, 880-888.	0.5	22
90	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. Journal of Virology, 2017, 91, .	1.5	23

#	Article	IF	Citations
91	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Vaccine Journal, 2017, 24, .	3.2	28
92	Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. Journal of Virology, 2017, 91, .	1.5	8
93	Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. Journal of Infectious Diseases, 2017, 215, S152-S159.	1.9	22
94	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Advances, 2017, 1, 2329-2342.	2.5	90
95	Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. Viruses, 2017, 9, 135.	1.5	3
96	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Medicine, 2017, 14, e1002435.	3.9	104
97	A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology, 2017, 14, 46.	0.9	2
98	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS ONE, 2017, 12, e0179597.	1.1	29
99	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	2.1	38
100	Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. PLoS ONE, 2016, 11, e0152038.	1.1	37
101	Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. PLoS ONE, 2016, 11, e0155702.	1.1	22
102	Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. Nature Communications, 2016, 7, 12131.	5.8	14
103	Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. Journal of Immunology, 2016, 197, 4603-4612.	0.4	44
104	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	3.7	41
105	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	2.7	47
106	Variability of the IFN-Î³ ELISpot assay in the context of proficiency testing and bridging studies. Journal of Immunological Methods, 2016, 433, 69-76.	0.6	6
107	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. Journal of Immunology, 2016, 197, 2726-2737.	0.4	34
108	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nature Reviews Drug Discovery, 2016, 15, 823-834.	21.5	51

#	Article	IF	Citations
109	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. Journal of Virology, 2016, 90, 8644-8660.	1.5	13
110	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. Journal of Virology, 2016, 90, 10362-10378.	1.5	26
111	Teaching advanced flow cytometry in Africa: 10 years of lessons learned. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 971-974.	1.1	2
112	Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. Aids, 2016, 30, 2815-2822.	1.0	4
113	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770.	15.2	197
114	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. Journal of Virology, 2016, 90, 2127-2134.	1.5	69
115	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	1.5	22
116	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. Journal of Virology, 2016, 90, 4951-4965.	1.5	23
117	The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. Mucosal Immunology, 2016, 9, 414-427.	2.7	19
118	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight, 2016, 1, e88522.	2.3	10
119	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS ONE, 2016, 11, e0153484.	1.1	20
120	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	2.1	145
121	Dual-Affinity Re-Targeting proteins direct T cellâ€“mediated cytolysis of latently HIV-infected cells. Journal of Clinical Investigation, 2015, 125, 4077-4090.	3.9	124
122	Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses. PLoS Pathogens, 2015, 11, e1004658.	2.1	42
123	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	6.0	191
124	An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. Journal of Virology, 2015, 89, 9154-9166.	1.5	14
125	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. Journal of Infectious Diseases, 2015, 211, 508-517.	1.9	57
126	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Science Translational Medicine, 2015, 7, 296ra112.	5.8	47

#	Article	IF	Citations
127	Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions. Immunity, 2015, 42, 591-592.	6.6	67
128	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. Journal of Virology, 2015, 89, 9952-9961.	1.5	55
129	Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C Î². Journal of Medicinal Chemistry, 2015, 58, 8638-8646.	2.9	35
130	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	1.5	35
131	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	5.1	66
132	Maternal HIV-1 envelopeâ€“specific antibody responses and reduced risk of perinatal transmission. Journal of Clinical Investigation, 2015, 125, 2702-2706.	3.9	68
133	Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. PLoS ONE, 2015, 10, e0118486.	1.1	42
134	The Human Antibody Response to the Surface of Mycobacterium tuberculosis. PLoS ONE, 2014, 9, e98938.	1.1	35
135	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	1.5	62
136	Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78.	0.9	26
137	Transcriptional and Posttranscriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-Specific CD8⁺T Cells That Mediate Virus Inhibition. Journal of Virology, 2014, 88, 9514-9528.	1.5	22
138	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. Journal of Immunology, 2014, 193, 6172-6183.	0.4	34
139	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	1.5	169
140	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. AIDS Research and Human Retroviruses, 2014, 30, A99-A99.	0.5	2
141	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAXÂ® B/E in RV144 Vaccinees. AIDS Research and Human Retroviruses, 2014, 30, A36-A36.	0.5	1
142	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Science Translational Medicine, 2014, 6, 228ra39.	5.8	412
143	Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. Journal of Immunological Methods, 2014, 409, 107-116.	0.6	34
144	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. Journal of Virology, 2014, 88, 2633-2644.	1.5	237

#	Article	IF	Citations
145	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	13.7	140
146	Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques. Journal of Virology, 2014, 88, 3329-3339.	1.5	80
147	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417.	1.5	16
148	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	13.5	266
149	The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-Î³ ELISpot) assay. Journal of Immunological Methods, 2014, 409, 31-43.	0.6	22
150	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved Human Peripheral Blood Mononuclear Cells. Journal of Immunological Methods, 2014, 409, 21-30.	0.6	19
151	Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. Journal of Immunological Methods, 2014, 409, 99-106.	0.6	24
152	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation, 2014, 124, 3879-3890.	3.9	99
153	Acute HIV-1 Infection in the Southeastern United States: A Cohort Study. AIDS Research and Human Retroviruses, 2013, 29, 121-128.	0.5	33
154	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	6.6	374
155	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. Journal of Virology, 2013, 87, 7828-7836.	1.5	59
156	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV_{mac251}at Challenge Exposure. Journal of Virology, 2013, 87, 3538-3548.	1.5	52
157	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. Journal of Virology, 2013, 87, 1708-1719.	1.5	130
158	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. Journal of Virology, 2013, 87, 6986-6999.	1.5	38
159	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9019-9024.	3.3	371
160	Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 505-508.	0.9	49
161	Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses. Current HIV Research, 2013, 11, 378-387.	0.2	82
162	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. PLoS ONE, 2013, 8, e74855.	1.1	76

#	Article	IF	Citations
163	Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. PLoS ONE, 2013, 8, e67574.	1.1	22
164	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. Journal of Clinical Investigation, 2013, 123, 380-93.	3.9	165
165	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. Journal of Virology, 2012, 86, 11521-11532.	1.5	357
166	CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection. Journal of Immunology, 2012, 188, 4289-4296.	0.4	63
167	Response to Comment on â€œCD4+CD8+T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infectionâ€. Journal of Immunology, 2012, 188, 5809.2-5810.	0.4	0
168	Initial HIV-1 Antigen-Specific CD8 ⁺ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. Journal of Virology, 2012, 86, 6835-6846.	1.5	56
169	Massive CD8 T Cell Response to Primary HIV Infection in the Setting of Severe Clinical Presentation. AIDS Research and Human Retroviruses, 2012, 28, 789-792.	0.5	4
170	Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nature Medicine, 2012, 18, 1673-1681.	15.2	130
171	Distinct Kinetics of Gag-Specific CD4+ and CD8+ T Cell Responses during Acute HIV-1 Infection. Journal of Immunology, 2012, 188, 2198-2206.	0.4	24
172	HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal Lineages. Journal of Virology, 2012, 86, 7496-7507.	1.5	76
173	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity, 2012, 37, 1-2.	6.6	131
174	SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine, 2012, 30, 1737-1745.	1.7	60
175	Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine, 2012, 30, 1830-1840.	1.7	14
176	Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology, 2012, 9, 89.	0.9	50
177	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 2012, 482, 89-93.	13.7	452
178	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	13.9	1,699
179	Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum. PLoS ONE, 2012, 7, e37648.	1.1	30
180	A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsâ˜†â˜†â˜†. Vaccine, 2011, 29, 1948-1958.	1.7	48

#	Article	IF	Citations
181	Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy. PLoS ONE, 2011, 6, e19617.	1.1	65
182	Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. Aids, 2011, 25, 941-949.	1.0	25
183	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. Journal of Virology, 2011, 85, 7029-7036.	1.5	210
184	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood, 2011, 117, 4805-4815.	0.6	193
185	Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis, 2011, 91, 250-256.	0.8	123
186	Highâ€throughput quantitative analysis of HIVâ€1 and SIVâ€specific ADCCâ€mediating antibody responses. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 603-612.	1.1	197
187	HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. Journal of Virology, 2011, 85, 9555-9567.	1.5	86
188	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. Journal of Virology, 2011, 85, 10518-10528.	1.5	141
189	Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Journal of Infectious Diseases, 2011, 204, 164-173.	1.9	105
190	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	2.1	90
191	Performance of serum-supplemented and serum-free media in IFNÎ³ Elispot Assays for human T cells. Cancer Immunology, Immunotherapy, 2010, 59, 609-618.	2.0	51
192	Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. Journal of Immunological Methods, 2010, 363, 42-50.	0.6	57
193	Loss of DNAMâ€1 contributes to CD8⁺ Tâ€cell exhaustion in chronic HIVâ€1 infection. European Journal of Immunology, 2010, 40, 949-954.	1.6	45
194	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. Journal of Virology, 2010, 84, 4998-5006.	1.5	110
195	Perforin and IL-2 Upregulation Define Qualitative Differences among Highly Functional Virus-Specific Human CD8+ T Cells. PLoS Pathogens, 2010, 6, e1000798.	2.1	111
196	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	4.2	562
197	HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC. PLoS Pathogens, 2009, 5, e1000414.	2.1	161
198	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine, 2009, 27, 243-249.	1.7	55

#	Article	IF	Citations
199	Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. Aids, 2009, 23, 897-906.	1.0	305
200	Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine, 2008, 26, 215-223.	1.7	53
201	Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design. Journal of Virology, 2008, 82, 7700-7710.	1.5	76
202	Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 203-212.	0.9	101
203	Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Current Opinion in HIV and AIDS, 2007, 2, 169-176.	1.5	20
204	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine, 2007, 25, 510-518.	1.7	85
205	Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. Clinical and Experimental Immunology, 2007, 149, 211-216.	1.1	15
206	Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods, 2006, 38, 274-282.	1.9	100
207	Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Review of Vaccines, 2006, 5, 505-516.	2.0	34
208	Excellent Safety and Tolerability of the Human Immunodeficiency Virus Type 1 pGA2/JS2 Plasmid DNA Priming Vector Vaccine in HIV Type 1 Uninfected Adults. AIDS Research and Human Retroviruses, 2006, 22, 678-683.	0.5	49
209	NaÃ¯ve T Cells Are Maintained in the Periphery During the First3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function. Journal of Clinical Immunology, 2005, 25, 462-472.	2.0	17
210	Highâ€Dose Recombinant Canarypox Vaccine Expressing HIVâ€1 Protein, in Seronegative Human Subjects. Journal of Infectious Diseases, 2005, 192, 1249-1259.	1.9	66
211	Standardization and Validation Issues of the ELISPOT Assay. , 2005, 302, 051-086.		60
212	Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials. AIDS Research and Human Retroviruses, 2005, 21, 68-81.	0.5	85
213	Longitudinal Assessment of Immune Response and Viral Characteristics in HIV-Infected Patients with Prolonged CD4+/Viral Load Discordance. AIDS Research and Human Retroviruses, 2005, 21, 13-16.	0.5	11
214	Immunodominance and Cross-Reactivity of B5703-Restricted CD8 T Lymphocytes from HIV Type 1 Subtype C-Infected Ethiopians. AIDS Research and Human Retroviruses, 2005, 21, 239-245.	0.5	10
215	Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4512-4517.	3.3	126
216	Absence of Immunodominant Anti-Gag p17 (SL9) Responses among Gag CTL-Positive, HIV-Uninfected Vaccine Recipients Expressing the HLA-A*0201 Allele. Journal of Immunology, 2004, 173, 2126-2133.	0.4	26

#	Article	IF	Citations
217	HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1â€“infected Ethiopians. Human Immunology, 2004, 65, 648-659.	1.2	11
218	Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitorâ€“Based Highly Active Antiretroviral Therapy: Immune Response and Viral Control. Journal of Infectious Diseases, 2003, 187, 1027-1037.	1.9	71
219	A Cluster of HIV Type 1 Subtype C Sequences from Ethiopia, Observed in Full Genome Analysis, Is Not Sustained in Subgenomic Regions. AIDS Research and Human Retroviruses, 2003, 19, 1125-1133.	0.5	14
220	A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. Journal of Immunological Methods, 2002, 260, 157-172.	0.6	299
221	Near Full-Length Clones and Reference Sequences for Subtype C Isolates of HIV Type 1 from Three Different Continents. AIDS Research and Human Retroviruses, 2001, 17, 161-168.	0.5	182
222	Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. Aids, 2001, 15, W1-W25.	1.0	18
223	CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunology Letters, 2001, 79, 37-45.	1.1	26
224	Effect of Highly Active Antiretroviral Therapy and Thymic Transplantation on Immunoreconstitution in HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 403-413.	0.5	43
225	Identification of Highly Conserved and Broadly Cross-Reactive HIV Type 1 Cytotoxic T Lymphocyte Epitopes as Candidate Immunogens for Inclusion inMycobacterium bovisBCG-Vectored HIV Vaccines. AIDS Research and Human Retroviruses, 2000, 16, 1433-1443.	0.5	49
226	CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3503-8.	3.3	46
227	Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1030-1035.	3.3	149
228	Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1396-1401.	3.3	231
229	IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clinical and Experimental Immunology, 1995, 101, 239-248.	1.1	52
230	Oligoclonal CD8 Lymphocytes from Persons with Asymptomatic Human Immunodeficiency Virus (HIV) Type 1 Infection Inhibit DIV-1 Replication. Journal of Infectious Diseases, 1995, 172, 964-973.	1.9	49
231	The Impact of HIV-1 Infection on Phenotypic and Functional Parameters of Cellular Immunity in Chimpanzees. AIDS Research and Human Retroviruses, 1993, 9, 647-656.	0.5	22
232	Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment. , 0, , 239-275.		1
233	Co-Administration of HIV Env Protein with DNA and/or NYVAC Vaccines in Humans Results in Earlier and Potent Generation of Anti-Env Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	0
234	Anti-V2 Antibodies Virus Vulnerability Revealed by Envelope V1 Deletion in HIV Vaccine Candidates. SSRN Electronic Journal, 0, , .	0.4	0